Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2018
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2018
SUMMARY
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Stromal Cell Derived Factor 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Stromal cell-derived factor 1 (SDF1) or C-X-C motif chemokine 12 (CXCL12) is a chemokine protein encoded by the CXCL12 gene. It activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1. The molecules developed by companies in Phase II and Preclinical stages are 4 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders, Hematological Disorders, Immunology, Infectious Disease and Toxicology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Angina (Angina Pectoris), B-Cell Chronic Lymphocytic Leukemia, Chemotherapy Effects, Chronic Heart Failure, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme (GBM), Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Myocardial Infarction, Neutropenia, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Primary Immune Deficiency (PID), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia and Traumatic Brain Injury.
Furthermore, this report also reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Stromal Cell Derived Factor 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Stromal cell-derived factor 1 (SDF1) or C-X-C motif chemokine 12 (CXCL12) is a chemokine protein encoded by the CXCL12 gene. It activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1. The molecules developed by companies in Phase II and Preclinical stages are 4 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders, Hematological Disorders, Immunology, Infectious Disease and Toxicology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Angina (Angina Pectoris), B-Cell Chronic Lymphocytic Leukemia, Chemotherapy Effects, Chronic Heart Failure, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme (GBM), Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Myocardial Infarction, Neutropenia, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Primary Immune Deficiency (PID), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia and Traumatic Brain Injury.
Furthermore, this report also reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
- The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
Cantex Pharmaceuticals Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
TikoMed AB
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles
1131-H12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1143-H1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Target CXCL-12 and VEGF for Renal Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Genistein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBsolvMIR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaptesed pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
Oct 03, 2017: NOXXON Publishes Preclinical Proof-of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors
Jul 04, 2017: NOXXON Announces First Patients Treated in Phase I/II Clinical Trial of NOX-A12 Combined with Keytruda in Metastatic Pancreatic and Colorectal Cancer
Oct 10, 2016: NOXXON Pharma Demonstrates Synergies between NOX-A12 and Therapies Working Through T Cells or NK Cells
Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease
Jan 20, 2016: NOXXON Pharma Hosts Key Opinion Leader Symposium
Jun 16, 2015: Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
May 26, 2015: Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treatment
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
Dec 05, 2014: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference
Nov 18, 2014: Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia
Nov 12, 2014: Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions
Sep 26, 2014: Cell Reports Publication on the Mechanism of Action of NOXXON’s Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
Cantex Pharmaceuticals Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
TikoMed AB
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles
1131-H12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1143-H1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Target CXCL-12 and VEGF for Renal Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Genistein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBsolvMIR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaptesed pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
Oct 03, 2017: NOXXON Publishes Preclinical Proof-of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors
Jul 04, 2017: NOXXON Announces First Patients Treated in Phase I/II Clinical Trial of NOX-A12 Combined with Keytruda in Metastatic Pancreatic and Colorectal Cancer
Oct 10, 2016: NOXXON Pharma Demonstrates Synergies between NOX-A12 and Therapies Working Through T Cells or NK Cells
Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease
Jan 20, 2016: NOXXON Pharma Hosts Key Opinion Leader Symposium
Jun 16, 2015: Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
May 26, 2015: Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treatment
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
Dec 05, 2014: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference
Nov 18, 2014: Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia
Nov 12, 2014: Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions
Sep 26, 2014: Cell Reports Publication on the Mechanism of Action of NOXXON’s Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Cantex Pharmaceuticals Inc, H1 2018
Pipeline by Juventas Therapeutics Inc, H1 2018
Pipeline by Noxxon Pharma AG, H1 2018
Pipeline by TikoMed AB, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Cantex Pharmaceuticals Inc, H1 2018
Pipeline by Juventas Therapeutics Inc, H1 2018
Pipeline by Noxxon Pharma AG, H1 2018
Pipeline by TikoMed AB, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Cantex Pharmaceuticals Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
TikoMed AB
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Cantex Pharmaceuticals Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
TikoMed AB
